Scientists at the University of Oxford, led by Professor Ahmed Ahmed, are designing OvarianVax, a vaccine which teaches the immune system to recognise and attack the earliest stages of ovarian cancer. The team will receive up to £600,000 for the study over the next three years to support lab research into the vaccine.
In this study, the CRUK-funded researchers will establish the targets for the vaccine. They will find out which proteins on the surface of early-stage ovarian cancer cells are most strongly recognised by the immune system and how effectively the vaccine kills mini-models of ovarian cancer called organoids.
If this research is successful, work will then begin on clinical trials of the vaccine. The hope is that in the future, women could be offered this vaccine to prevent ovarian cancer in the first place.
Read the full story on the MRC Weatherall Institute of Molecular Medicine (MRC WIMM) website.
more recommended stories
Caffeine and SIDS: A New Prevention TheoryFor the first time in decades,.
Microbial Metabolites Reveal Health InsightsThe human body is not just.
Reelin and Cocaine Addiction: A Breakthrough StudyA groundbreaking study from the University.
Preeclampsia and Stroke Risk: Long-Term EffectsPreeclampsia (PE) – a hypertensive disorder.
Statins and Depression: No Added BenefitWhat Are Statins Used For? Statins.
Azithromycin Resistance Rises After Mass TreatmentMass drug administration (MDA) of azithromycin.
Generative AI in Health Campaigns: A Game-ChangerMass media campaigns have long been.
Molecular Stress in Aging Neurons ExplainedAs the population ages, scientists are.
Higher BMI and Hypothyroidism Risk StudyA major longitudinal study from Canada.
Therapeutic Plasma Exchange Reduces Biological AgeTherapeutic plasma exchange (TPE), especially when.
Leave a Comment